Pharmacoeconomic comparisons of venlafaxine and mirtazapine in patients with treatment-resistant major depression / 中华行为医学与脑科学杂志
Chinese Journal of Behavioral Medicine and Brain Science
; (12): 327-330, 2014.
Article
in Zh
| WPRIM
| ID: wpr-447929
Responsible library:
WPRO
ABSTRACT
Objective To compare the cost-effectiveness and cost-utility of venlafaxine and mirtazapine in patients with treatment-resistant major depression (TRD).Methods One hundred and five patients with TRD were enrolled in this study and grouped into venlafaxine treatment (n=50) and mirtazapine treatment (n=55) based on the double-blind randomization scheme generated by computer.The treatment costs of antidepressants during 8 weeks were calculated,the rates of clinical response and remission were taken as treatment effectiveness,and the quality-adjusted life years (QALYs) as treatment utility.The descriptive analysis and nonparametric test were used to compare the cost-effectiveness and cost-utility of different groups.Results During 8 weeks,the treatment cost of antidepressant was ¥ 1 396.44 for venlafaxine and ¥ 1 206.90 mirtazapine,and the difference between two groups was ¥ 189.54.The cost-effectiveness ratios between venlafaxine and mirtazapine were very close (differed ¥ 0.06 for remission rate and ¥ 1.08 for response rate respectively).There was no significant difference for cost-utility ratios between two groups (physical functioning Z=-0.15,P>0.05 ; mental health Z=-0.54,P>0.05).Conclusion Both cost-effectiveness and cost-utility of venlafaxine in patients with TRD are close between venlafaxine and mirtazapine.
Full text:
1
Database:
WPRIM
Type of study:
Clinical_trials
Aspects:
Patient_preference
Language:
Zh
Journal:
Chinese Journal of Behavioral Medicine and Brain Science
Year:
2014
Document type:
Article